share_log

上海医药(601607.SH):叶酸片通过仿制药一致性评价

Shanghai Pharmaceutical (601607.SH): consistency evaluation of folic acid tablets through generic drugs

Zhitong Finance ·  Aug 4, 2022 16:15

Zhitong Financial APP News, Shanghai Pharmaceutical (601607.SH) issued a notice that recently, the folic acid tablets (5mg) of Changzhou Pharmaceutical Factory, a subsidiary of the company, received a "notice of approval for supplementary drug application" issued by the State Drug Administration, which was the first in China to pass the consistency evaluation of the quality and efficacy of generic drugs.

Folic acid belongs to B vitamins. Folic acid is a kind of vitamins that maintain cell function, metabolism and growth. Folic acid plays an important role in nucleic acid and protein synthesis, amino acid transformation, purine synthesis and DNA synthesis and metabolism. Many enzyme reactions in the body play a coenzyme role. It is mainly used for folic acid deficiency caused by various causes and megaloblastic anemia caused by folic acid deficiency and folic acid deficiency caused by chronic hemolytic anemia. it can prevent fetal neural tube defects for women who plan to become pregnant and are known to be at risk. As of the date of announcement, the company has invested about 5.8935 million yuan in R & D cost for the consistency evaluation of the drug. According to the IQVIA database, the purchase amount of the drug hospital in 2021 is 187.41 million yuan. In 2021, the sales income of Changzhou Pharmaceutical Factory was 102.32 million yuan.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment